* Please note that the following agenda timings are Eastern Standard Time.  


Coffee morning to meet your peers ahead of the conference

9:00 am Chair’s Opening Remarks

Driving Future Clinical Success

9:10 am Lessons Learned & Looking Beyond – Novartis’ Journey with TGF-β


  • First-in-human data – from biomarker and clinical outcomes
  • Potential insights into patient selection
  • What did we learn from other studies so far and how does this inform Ph2+ design?

9:40 am Panel Discussion: Realizing a Circular Approach to Enhance Clinical Success


  • Developing a closer relationship between preclinical and clinical investigators
  • Coming back to models to understand mechanisms behind what is seen in human
  • Leveraging feedback from preclinical models to guide clinical decisions

10:20 am
Morning Networking Break


Meet and connect with your peers in this dedicated networking session

Preclinical Track

Overcoming the Complexity of TGF-β Pathways & Immune Cell Interactions

Chair: Divya Mathur, Director of Immuno-Oncology, Regeneron Pharmaceuticals

11:00 am Cancer Immunotherapy using TGF-β Conditioned Gamma Delta T-Cells


• TGF-β enhances the yield and intrinsic anti-tumour activity of gd T-cells expanded from peripheral blood
• Both unmodified and CAR-engineered cells demonstrate superior anti-tumour activity in a range of disease models

11:30 am Exploiting TGF-β Biology in Genotoxic Cancer Therapy


• Radiation and chemotherapy induce TGF-β activity
• TGF-β regulates DNA repair pathways
• Transcriptomic signatures classifying cancers according to TGF-β signaling competency identify a specific DNA damage vulnerability

Clinical Track

Defining Clinical Biomarkers to Maximize the Therapeutic Potential of TGF-β

11:00 am Development of a Comprehensive Biomarker Strategy to Support DRAGON, a Phase 1 Clinical Trial of SRK-181, the Latent TGFβ1 Inhibitor


• Preclinical data demonstrate that combining SRK-181 with a PD-1 inhibitor modifies the immune profile within the tumor immune microenvironment
• A comprehensive biomarker strategy is being developed to support the ongoing DRAGON trial and further explore the mechanism of action of SRK-181
• Ongoing evaluation of immune biomarkers and establishment of image analysis-based methods in preclinical studies will be presented

11:30 am Determining the Promise of TGF-β With Chemotherapeutic Agents

  • Davide Melisi Associate Professor of Medical Oncology, University of Verona


• Exploring the different mechanisms seen when combining TGF-β inhibitors with chemotherapeutic agents
• Investigating the clinical development of this combination approach in pancreatic cancer
• Addressing the importance of patient selection in this clinical success

12:00 pm Networking Lunch

Diving into the TGF-β Paradox in Immuno-Oncology

Chair: Divya Mathur, Director of Immuno-Oncology, Regeneron Pharmaceuticals

1:00 pm Fibroblast Subpopulations & their Role in the Tumor Microenvironment

  • James Legg Senior Vice President – Research & Early Development, Mestag Therapeutics


• Cancer associated fibroblasts are one of the most abundant cell types in the TME
• Recent advances in our understanding of fibroblast populations gained through single cell sequencing and other technologies demonstrates that different populations of fibroblasts are present in the TME
• These insights are helping us understand some of the cues (for example TGF-β and IL1) that are important in regulating these populations and their ability to play key roles in the TME such as promotion of immune suppression and tumor progression

1:30 pm Exploring the Role of TGF-β in Regulating the Immune Environment

  • Mark Travis Head of Division of Infection, Immunity & Respiratory Medicine, University of Manchester


• Reviewing the suppressive impact of TGF-β activation on immune cells in health and disease
• Advanced study of the activation of TGF-β via different immune cells
• Potential of targeting TGF-β activation mechanisms in the TME

Preventing & Understanding Toxicity of TGF-β-Targeted Therapeutics

1:00 pm Safety Observations from Small Molecule Inhibitors of ALK5 in Patients


• How to overcome the non-clinical toxicity in animals
• PK/PD modelling and the subsequent validation in patients
• Safety monitoring in the clinic

1:30 pm Determining the Side Effects of TGF-β Inhibition to Drive Safe Clinical Trials


• Highlighting the common side effects with TGF-β inhibition including increased breathing risk and hypertension
• Understanding these side effects in order to manage them correctly in clinic
• Determining the optimal therapeutic window and dosing regiment to balance efficacy and side effects in clinical trials

2:00 pm
Afternoon Networking Break

Maximizing TGF-β’s Therapeutic Potential Beyond IO

2:30 pm A Novel IL-2-TGF-β Fusion Protein for Induction & Expansion of Regulatory T Cells for Autoimmune & Inflammatory Diseases

  • Anish Suri President & Chief Scientific Officer, Cue Bio

3:00 pm Harnessing the Parallels of TGF-β Drug Development in Fibrosis & Oncology


  • Assessing how TGF-β contributes to fibrosis through signaling pathways and it’s effect on myofibroblasts
  • Evaluating what treatments are in the field to date
  • Understanding TGF-β in lung fibrosis and the use of biomaterials

3:30 pm Chair’s Closing Remarks

3:40 pm End of Day Two